Ken Griffin
MGRX icon

Ken Griffin’s Mangoceuticals MGRX Stock Holding History

Ken Griffin’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,880
Closed -$41.2K – 14843
2024
Q2 		$41.2K Buy
8,880
+1,253
+16% +$5.8K ﹤0.01% 11963
2024
Q1 		$25.2K Buy
7,627
+6,140
+413% +$24.4K ﹤0.01% 12844
2023
Q4 		$6.18K Sell
1,487
-1,658
-53% -$14.7K ﹤0.01% 13369
2023
Q3 		$41.5K Buy
+3,145
New +$58.9K ﹤0.01% 11965

Other funds holding MGRX

ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
PEAK6 Investments Chicago, Illinois $44.8B AUM 19.99% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Ken Griffin's MGRX Position: Q3 2024 in Review

Ken Griffin sold out of Mangoceuticals (MGRX) in Q3 2024, closing a stake of 8,880 shares — an estimated $41.2K sold.

Ken Griffin first reported a position in MGRX in Q3 2023 and held it in 4 quarters. The position peaked at $41.5K in Q3 2023. 13 funds tracked by Wall St. Rank hold MGRX as of Q3 2024.

  • Ken Griffin reported no remaining Mangoceuticals position as of Q3 2024 after selling out during the quarter.
  • Ken Griffin sold 8,880 Mangoceuticals shares in Q3 2024, an estimated $41.2K.
  • Ken Griffin first reported a position in Mangoceuticals in Q3 2023 and held it in 4 quarters.
  • Ken Griffin's Mangoceuticals position peaked at $41.5K in Q3 2023.
  • 13 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.